ACLX Arcellx, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
ACLX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$64.11
Analyst Target
$110.53
+72.4%
Upside
52W High
$94.07
52W Low
$47.86
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 21, 2026
Market cap
$3.71B
P/E
N/A
ROE
-47.2%
Profit margin
N/A
Debt/Equity
0.12
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
ACLX exhibits severe financial distress despite a strong analyst consensus, as reflected in its Piotroski F-Score of 1/9—indicating weak operational and financial health. The company reports negative profitability across all key margins, with a staggering -1248.25% operating margin and -47.18% ROE, while revenue has collapsed by 81% YoY. Although the debt/equity ratio is low (0.12) and liquidity is high (current ratio 3.99), these are insufficient to offset deteriorating fundamentals. Insider selling totaling $7.12M in six months and a bearish technical trend further undermine confidence. The stock trades at a premium valuation (Price/Sales 103.27) despite negative earnings and no intrinsic value, suggesting overvaluation driven by speculative growth expectations.
Key Strengths
Strong analyst consensus with 'strong_buy' recommendation from 17 analysts
High liquidity with current and quick ratios above 3.9, indicating robust short-term solvency
Low debt/equity ratio (0.12) suggesting minimal leverage risk
Historical periods of significant earnings surprise (e.g., +184% in Q1 2024)
Significant 5-year price appreciation (+281.6%), indicating strong investor interest
Key Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and poor operational efficiency
Negative and deteriorating revenue growth (-81% YoY) and earnings (YoY EPS down -106.2%)
Massive insider selling (13 transactions, $7.12M) with no buys in last 6 months
No profitability: all margins are negative, including ROE (-47.18%) and ROA (-21.34%)
Valuation is extremely stretched (Price/Sales 103.27) with no Graham Number or intrinsic value available
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
21
Weak
20
30
40
15
0
AI Verdict
Weak
Key drivers: Extremely low Piotroski F-Score (1/9), Negative and declining revenue and earnings, High insider selling activity, No profitability or cash flow generation, Premium valuation without earnings support
Confidence
85%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Low debt/equity ratio (0.12) reduces financial risk
- High current and quick ratios (3.99, 3.93) indicate strong liquidity
Watchpoints
- No Graham Number or intrinsic value available
- Price/Sales of 103.27 is extremely high for a non-profitable firm
- Forward P/E of -18.45 reflects deep losses, not value
Future
30/100
Ref Growth rates
Positives
- Analyst target price of $110.53 implies significant upside from current $64.11
- Historical volatility in earnings surprises suggests potential for recovery
Watchpoints
- Revenue down 81% YoY, indicating business contraction
- Earnings growth is deeply negative (-106.2% YoY)
- No clear path to profitability or sustainable growth
Past
40/100
Ref Historical trends
Positives
- Significant past earnings surprises (e.g., +184% in Q1 2024)
- 5-year price return of +281.6% shows strong historical performance
Watchpoints
- Consistent earnings misses in recent quarters (e.g., -53.0%, -83.4%, -96.2%)
- Most recent Q/Q EPS growth is -5.3%
- Historical losses are extreme (e.g., -557.6% surprise in Q1 2022)
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt/equity (0.12) and high liquidity (current ratio 3.99)
- No Altman Z-Score available, but low leverage reduces immediate distress risk
Watchpoints
- Piotroski F-Score of 1/9 is critically low, indicating severe financial distress
- Negative ROE, ROA, and operating margin suggest poor capital efficiency
- No free cash flow or operating cash flow data available
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend strength is 0/100, indicating no dividend policy
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$64.11
Analyst Target
$110.53
Upside/Downside
+72.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACLX and closest competitors.
Updated 2026-02-20
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACLX
Arcellx, Inc.
Primary
|
+281.6% | +132.1% | -2.3% | -10.1% | -6.9% | -6.4% |
|
ADMA
ADMA Biologics, Inc.
Peer
|
+528.9% | +356.1% | +0.1% | -9.6% | -7.3% | +0.1% |
|
BLLN
BillionToOne, Inc.
Peer
|
-19.6% | -19.6% | -19.6% | -19.6% | +1.4% | -1.3% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-52.2% | +28.8% | +18.2% | -6.8% | -10.3% | +8.9% |
|
ARQT
Arcutis Biotherapeutics, Inc.
Peer
|
-3.6% | +63.3% | +92.7% | +76.3% | -11.0% | +1.4% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-18.45
PEG Ratio
N/A
P/B Ratio
8.4
P/S Ratio
103.27
EV/Revenue
95.75
EV/EBITDA
-14.58
Market Cap
$3.71B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-1248.25%
Gross Margin
N/A
ROE
-47.18%
ROA
-21.34%
Growth
Revenue and earnings growth rates
Revenue Growth
-81.0%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.12
Low debt
Current Ratio
3.99
Strong
Quick Ratio
3.93
Excellent
Cash/Share
$7.98
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-26
$N/A
2025-11-05
$-0.99
+4.1% surprise
2025-08-07
$-0.94
+8.9% surprise
2025-05-08
$-1.13
-53.0% surprise
Healthcare Sector Comparison
Comparing ACLX against 146 companies in the Healthcare sector
(11 bullish, 60 neutral, 75 bearish)
Return on Equity (ROE)
-47.18%
This Stock
vs
-56.86%
Sector Avg
-17.0%
(Below Avg)
Debt to Equity
0.12
This Stock
vs
2.68
Sector Avg
-95.6%
(Less Debt)
Revenue Growth
-81.0%
This Stock
vs
62.23%
Sector Avg
-230.2%
(Slower)
Current Ratio
3.99
This Stock
vs
3.45
Sector Avg
+15.6%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACLX
Arcellx, Inc.
|
BEARISH | $3.71B | - | -47.2% | -% | $64.11 | |
|
ADMA
ADMA Biologics, Inc.
|
NEUTRAL | $3.84B | 18.72 | 63.2% | 42.9% | $16.1 | |
|
BLLN
BillionToOne, Inc.
|
NEUTRAL | $4.01B | - | -% | -4.4% | $87.57 | |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
BULLISH | $4.06B | 15.48 | 35.0% | 24.9% | $23.99 | |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
NEUTRAL | $3.21B | - | -28.2% | -13.9% | $26.2 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-19 | GILSON MICHELLE | Chief Financial Officer | Sale | 8,384 | $572,568 |
| 2026-02-17 | GILSON MICHELLE | Chief Financial Officer | Sale | 11,291 | $784,783 |
| 2026-02-11 | ELGHANDOUR RAMI | Chief Executive Officer | Gift | 218,500 | - |
| 2026-02-11 | ELGHANDOUR RAMI | Chief Executive Officer | Gift | 198,000 | - |
| 2026-01-20 | LUBNER DAVID CHARLES | Director | Sale | 6,000 | $450,000 |
| 2026-01-20 | LUBNER DAVID CHARLES | Director | Option Exercise | 6,000 | $37,680 |
| 2026-01-14 | HEERY CHRISTOPHER RYAN | Officer | Sale | 5,882 | $402,997 |
| 2026-01-13 | HEERY CHRISTOPHER RYAN | Officer | Sale | 7,437 | $487,213 |
| 2026-01-12 | HEERY CHRISTOPHER RYAN | Officer | Sale | 6,131 | $393,286 |
| 2026-01-06 | HEERY CHRISTOPHER RYAN | Officer | Stock Award | 42,605 | - |
| 2026-01-06 | GILSON MICHELLE | Chief Financial Officer | Stock Award | 56,366 | - |
| 2026-01-06 | ELGHANDOUR RAMI | Officer and Director | Stock Award | 164,548 | - |
| 2025-11-17 | HEERY CHRISTOPHER RYAN | Officer | Sale | 340 | $30,600 |
| 2025-10-15 | GILSON MICHELLE | Chief Financial Officer | Sale | 5,364 | $488,315 |
| 2025-10-06 | GILSON MICHELLE | Chief Financial Officer | Sale | 5,946 | $511,603 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
17 analysts
Needham
2026-02-05
Buy
Buy
HC Wainwright & Co.
2026-02-04
Buy
Buy
Wells Fargo
2025-12-22
Overweight
Canaccord Genuity
2025-12-08
Buy
Buy
Needham
2025-12-08
Buy
Buy
Wolfe Research
2025-11-18
Peer Perform
Canaccord Genuity
2025-11-03
Buy
Buy
Past News Coverage
Recent headlines mentioning ACLX from our newsroom.
Newest → oldest
No matching news yet.